Dr. Mathias Bostrom, MD, is a specialist in hip and knee surgery, especially in complex reconstructions and the treatment of musculoskeletal infections. He enjoys the challenges, intellectual and physical, of difficult and complex cases. He is expert in merging old and new technologies, including alternative bearings for younger patients: ceramic, metal, and plastic, where they are appropriate.
Dr. Bostrom is particularly sensitive to the quality of bone healing and strength. His research focuses on enhancing bone formation, bone regeneration, bone and cartilage healing, and bone biology. He is the author of over 60 journal articles and book chapters. He is a member of numerous prestigious academic orthopedic societies such as the Hip Society, Orthopaedic Research Society, and International Society for Fracture Repair. In addition, he serves as a member of several review panels, including the Musculoskeletal tissue engineering study section of the National Institute of Health.
Dr. Bostrom received his education and training at the University of Virginia and Johns Hopkins. After completing his residency and two fellowships at Hospital for Special Surgery and New York Hospital – Cornell Medical Center, he started his orthopedic practice at Hospital for Special Surgery in 1996.
Attending Orthopaedic Surgeon, Hospital for Special Surgery
Professor of Orthopaedic Surgery, Weill Cornell Medical College
Total knee and hip replacement
Hip and knee revisions
Philip D. Wilson, Jr. Teaching Award, 1999
Eastern Orthopaedic Association Founder Award, 1996
Knee Society Award, 1994
Blue Cross HMO POS
Blue Cross PPO
Blue Cross Pathway
Blue Cross Pathway Enhanced
Medicare (Status: Non-Par using Medicare Limited Fee Schedule)
If your particular insurance plan is not listed, you may still have coverage subject to the availability of 'out-of-network' benefits. Please do not hesitate to contact our office if you have questions regarding your insurance coverage.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Bostrom as of March 24, 2015.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
MD, Johns Hopkins University School of Medicine
Orthopaedic Surgery, Hospital for Special Surgery
Hip/Knee Fellowship, Adult Reconstruction, Hospital for Special Surgery
American Board of Orthopaedic Surgery
Gardner MJ, van der Meulen MC, Carson J, Zelken J, Ricciardi BF, Wright TM, Lane JM, Bostrom MP. Role of parathyroid hormone in the mechanosensitivity of fracture healing. J Orthop Res. 2007 Nov;25(11):1474-80.
Carson JS, Bostrom MP. Synthetic Bone Scaffolds and Fracture Repair. Injury. 2007 Mar;38 Suppl 1:S33-7. Review.
For more publications, please see the PubMed listing.
The overall aim of my laboratory efforts continues to be gaining a better understanding of the fundamental principles of bone healing and to use these principles in the development of methods to improve bone healing. Current projects include the use of a multigene assay to quantitatively describe the genetic cascade of growth factors and cytokines during the process of fracture healing. This work will be done in collaboration with Paul Cannon, Ph.D. at Roche Bioscience since he has access to gene chip technology. In addition to this work in the rat fracture model, we will also be collaborating with the scientists at Roche Bioscience in studying the gene expression in a number of human musculoskeletal tissues harvested during total joint arthroplasty procedures.
In collaboration with Nancy Camacho, Ph.D., we are also using Fourier transform infrared microscopy to better define the mineral and organic matrix characteristics of fracture callus. To achieve this goal we have recently developed a fracture model in the mouse and will be utilizing this model to determine the effects of alendronate treatment on the healing normal fractures as well as fractures in OIM mice. My collaboration with Dr. Camacho is also proceeding on developing a FTIR probe to study ultrastructural properties of cartilage and bone in human tissues harvested from total joint arthroplasties performed by me. In the future the use of FTIR methodology may prove to be of significant value in assessing the regeneration of cartilage through tissue engineering in both animal models and clinically. Thus a major thrust this upcoming year will be made with Dr. Camacho to assess the feasibility of using this technology in such a manner.
One of my major development projects over the last several years, in close association with Tim Wright Ph.D. and Marjolein van der Mullen Ph.D., has been the development of an in vivo cyclic loading device in rabbits to study the remodeling process of trabecular bone. This remodeling process has been studied with and without the use of exogenous osteogenic growth factors, and we are currently completing a series of experiments investigating the effects of magnitude, frequency and duration of load on trabecular bone. This work is being partially funded by a generous grant from the Oxnard Foundation and a development and feasibility grant from the NIH. The eventual goal is to improve bone adaptation around total joint implants, and the work will continue to proceed in this direction in the upcoming year with some modification of the loading device currently utilized with the goal of scaling it down to be used in rodents. This modification of the device will be made in collaboration with Dr. Per Aspenberg at the University of Lund in Lund, Sweden. With the anticipated arrival of a micro-CT device at HSS in the upcoming months work on this project as well as other collaborative bone projects will be significantly enhanced.
Clinically, I continue with efforts to establish RSA as outcome measure for total joint arthroplasty. The equipment for performing the studies is on site and we have obtained IRB approval to proceed with these studies. Finally, in the clinical arena, in collaboration with Dr. Kudryck at the New York Blood Center, I hope to be investigating the use of a novel fibrinogen assay to assess the role of the clotting cascade in patients with total hip arthroplasties.
Monday – Friday, 9:00am – 5:00pm
Hospital for Special Surgery
535 East 70th Street
New York, NY 10021
Helen Hayes Rehabilitation Hospital
51 N Route 9W
West Haverstraw, NY 10993
Personal Website: http://mathiasbostrom.com